skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

December 5, 2016

 

Roche and Good Start Genetics Announce Marketing Agreement

 

Good Start Genetics announced that it has entered into a collaborative agreement with Roche Holding AG, in which Roche will begin selling Good Start Genetic’s GeneVu laboratory developed screening test in combination with its proprietary Harmony non-invasive prenatal test in the United States. While Harmony specifically detects Down syndrome, Edward syndrome and Patau syndrome, GeneVu offers an array of additional tests that patients and physicians may choose from, including ethnicity-specific tests for blood disorders. This agreement will therefore enable Roche to offer a more complete range of screening services to healthcare professionals and patients across the United States, and also enhance Good Start Genetic’s reputation in the market.

 

See more on the GeneVu and Harmony tests on Meddevicetracker.

 

December 6, 2016

 

Medtronic’s Endurant II/IIs Stent Graft System Receives CE Mark

 

Medtronic announced that is has obtained CE Mark approval for the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients using a ChEVAR procedure, a parallel graft chimney technique that uses commercially available balloon expandable covered stents combined with a standard aortic stent graft. This expanded indication in the European Union will enable the Endurant II/IIs stent graft system to be used in patients with complex aneurysms with short aortic neck lengths ≥2 mm, expanded from the prior neck length indication ≥10 mm. Prior research has demonstrated that standardized use of the Endurant II/IIs stent graft system with ChEVAR in 128 patients is associated with 100 percent technical success, statistically significant aneurysm sac regression (p = .001), 95.7 percent primary patency of the chimney grafts, and a low incidence of chimney related reinterventions. This expanded approval will at first be commercialized in Europe, and then into additional countries recognizing the CE Mark.

 

See more on the Endurant II on Meddevicetracker.

 

December 7, 2016

 

Abiomed Impella CP Receives Expanded FDA Approval

 

Abiomed announced it has expanded its U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for Impella heart pump use in high-risk percutaneous coronary interventions (PCI) to include the Impella CP heart pump. The Impella CP heart pump was previously cleared in April 2016 for treatment of ongoing cardiogenic shock; however, recent data from Abiomed’s Protect I and Protect II clinical studies has demonstrated that use of the Impella CP in high-risk PCI procedures significantly enhances clinical outcomes. In lieu of this expanded indication, the Impella CP joins the Imepella 2.5 as the only hemodynamic support devices proven safe and effective by the FDA for high-risk PCI and Acute Myocardial Infarction (AMI) cardiogenic shock.

 

See more on the Impella CP on Meddevicetracker.

 

December 8, 2016

 

St. Jude Medical Receives CE Mark

 

St. Jude Medical has obtained CE Mark approval for full-body magnetic resonance (MR) conditional labeling of the Proclaim Elite Spinal System, which had previously been cleared for MRI scanning of only the head and extremity areas. This prior restriction in labelling was considered a significant barrier to patients who sought relief for chronic pain by implantation of the Proclaim Elite, because it imposed a limitation to their diagnostic testing options. However, with this approval, in combination with a similar approval recently granted by the United States FDA, the limitations to diagnostic testing for these patients has been significantly mitigated. Patients who have received implantation of the Proclaim Elite SCS System may now undergo comprehensive MRI diagnostic testing while also retaining access to the medical treatment they need.

 

See more on the Proclaim Elite on Meddevicetracker.

 

 

 



 

 

Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    <p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare &amp; biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: